PHASE 2 STUDY OF ACALABRUTINIB IN IBRUTINIB-INTOLERANT PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Authors :: R.K. Raman
M.M. Frigault
Kerry A. Rogers
C. Quah
John N. Allan
Morton Coleman
Philip A. Thompson
M.H. Wang
Thomas J. Kipps
Jeffrey P. Sharman
R. Izumi
Bruce D. Cheson
Source :: Hematological Oncology. 37:60-61
Publication Year :: 2019
Publisher :: Wiley, 2019.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Chronic lymphocytic leukemia
Phases of clinical research
Hematology
General Medicine
medicine.disease
chemistry.chemical_compound
chemistry
Ibrutinib
Internal medicine
Relapsed refractory
medicine
Acalabrutinib
business

Full Text Access

Tools